Boehringer to acquire Actimis in $515 million deal
INGELHEIM, Germany and SAN DIEGO Boehringer Ingelheim announced Tuesday that it will acquire Actimis Pharmaceuticals in a deal worth $515 million.
The acquisition will be a structured buyout, dependent on milestones with Actimis’ asthma drug AP768, currently in Phase I testing. Should testing progress to Phase III, Boehringer will acquire all of Actimis’ shares. The deal will be complete once the development program is finished.
Founded in 1885, the Boehringer is one of the world’s 20 leading pharmaceutical companies. The family-owned company has headquarters in Ingelheim, Germany, and operates in 47 countries.
Actimis specializes in research and development of drugs to treat respiratory, inflammatory and autoimmune diseases. Headquartered in San Diego, it was spun off from Bayer Healthcare in 2004.
Major drug companies agree to six-month moratorium on DTC ads
WASHINGTON Under pressure from some of the top members of the House of Representatives, top drug companies, including Merck, Johnson & Johnson and Pfizer, are agreeing on a six-month moratorium on advertising new drugs to consumers and will limit how doctors are used in their ads, according to reports.
The changes were unveiled in letters the manufacturers sent the House Energy and Commerce Committee responding to a request from committee chairman John Dingell, D-Mich., and Rep. Bart Stupak, D-Mich., who head the committee’s oversight and investigations panel.
Dingell and Stupak had wanted the companies to impose a two-year voluntary moratorium on advertising of new prescription drugs to consumers – and possibly even longer in the case of drugs for which not all studies have been completed. The lawmakers also asked the drug companies to limit the use of doctors in their advertising and agree to “black box” warnings on ads if the Food and Drug Administration requested them.
In the letters, executives of J&J, Merck, Merck/Schering-Plough and Pfizer agreed to take several steps, while the Pharmaceutical Research and Manufacturers of America agreed to hold further meetings with the committee. The companies will start following the American Medical Association’s guidelines about using actors to portray doctors, and at least one marketer, J&J, said it would not use doctors in ads to discuss the benefits of a drug.
The drug companies said in their letters that the six-month moratorium formalized industry practice, which is to educate doctors before moving to consumer communications. “We drugs [that] requires that our operating companies spend at least six months after approval have adopted internal guiding practices on direct-to-consumer advertising for prescription of a new medicine educating health professionals before commencing a direct-to-consumer advertising campaign,” wrote William Weldon, chairman and chief executive officer of J&J. He added that the company “does not believe a particular fixed period of time for an advertising moratorium is appropriate in all circumstances.”
Dingell and Stupak said they were pleased with the response, but wanted the drug companies to go further, with a two-year limit.
FDA grants Mylan approval for generic Avalide application
PITTSBURGH The Food and Drug Administration has granted tentative approval to Mylan Pharmaceuticals for its application for a generic version of Sanofi Aventis’ Avalide Tablets.
The tablets, generically known as irbesartan and hydrochlorothiazide, are used to treat hypertension. The application is among the 92 that Mylan has submitted to the FDA for approval.
Avalide had U.S. sales of about $288 million for the 12 months ended March 31, according to IMS Health.